LLY
Eli Lilly and Company
LLY has the edge over TKNO overall, supported by lower modeled downside and stronger fundamentals.
TKNO
Alpha Teknova, Inc.
TKNO's outlook is improving, though it still trails on the overall score.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
TKNO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Under pressure | |
| Strong |
TKNO's revenue and balance sheet are currently healthy, but its profitability and cash flow are under pressure.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
TKNO PE Valuation
TKNO has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
TKNO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect TKNO's losses to shrink, with revenue growing.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over TKNO on earnings quality, reporting a profit while its opponent remains loss making.
TKNO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.28 | +$0.05 |
| Q2 2026 | -$0.30 | +$0.10 |
| Q1 2026 | -$0.31 | +$0.15 |
| Q4 2025 | -$0.32 | +$0.25 |
| Q3 2025 | -$0.33 | +$0.41 |
| Q2 2025 | -$0.40 | +$0.53 |
| Q1 2025 | -$0.46 | +$0.59 |
| Q4 2024 | -$0.57 | +$0.59 |
TKNO is still losing money, but far less than before: $0.28 per share over the past year, against $1.83 at its worst in mid-2023.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over TKNO on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over TKNO on profitability, with a higher operating margin.
TKNO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $12.7M | +22% |
| Q2 2026 | $12.2M | +18% |
| Q1 2026 | $11.1M | +13% |
| Q4 2025 | $10M | +7.8% |
| Q3 2025 | $10.5M | +9.2% |
| Q2 2025 | $10.3M | +7% |
| Q1 2025 | $9.8M | +5.4% |
| Q4 2024 | $9.3M | +18% |
TKNO's revenue has grown year over year for nine quarters in a row: $13M last quarter, up 22% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -25% | +13 points |
| Q2 2026 | -24% | +9.2 points |
| Q1 2026 | -39% | +12 points |
| Q4 2025 | -46% | +15 points |
| Q3 2025 | -38% | +39 points |
| Q2 2025 | -33% | +20 points |
| Q1 2025 | -51% | +35 points |
| Q4 2024 | -61% | +77 points |
TKNO's operating margin was −25% last quarter, up 13 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over TKNO on cash generation, producing positive trailing cash flow while its opponent burns cash.
TKNO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.4M | +$969K |
| Q2 2026 | -$596K | +$1.7M |
| Q1 2026 | -$3.6M | +$729K |
| Q4 2025 | -$810K | +$693K |
| Q3 2025 | -$2.4M | +$23K |
| Q2 2025 | -$2.3M | +$645K |
| Q1 2025 | -$4.3M | +$2.4M |
| Q4 2024 | -$1.5M | +$1.7M |
TKNO has burned cash in almost every quarter: −$6M over the past year, against −$10M the year before.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
TKNO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2021 | -47.1x | Net Cash |
| Q1 2021 | -0.5x | Net Cash |
| Q4 2020 | -0.5x | Net Cash |
TKNO has more cash than debt.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
TKNO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 61.0 | Neutral |
| Stochastic | 64.2 | Neutral |
TKNO's weekly RSI is 61 (neutral) and its Stochastic is 64 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
TKNO PE vs Healthcare Sector
TKNO has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
TKNO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $8.02 | 3.4% above |
| 20 week MA | $7.02 | 18% above |
| 50 week MA | $4.94 | 68% above |
| 100 week MA | $5.41 | 53% above |
| 200 week MA | $4.43 | 87% above |
TKNO is in an uptrend: it's above all five of its weekly moving averages, and 87% above its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has finished every year since 2020 higher, and it's up 32% so far in 2026.
TKNO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $25.0 | $20.4 | -19% |
| 2022 | $20.4 | $5.14 | -75% |
| 2023 | $5.14 | $3.73 | -27% |
| 2024 | $3.73 | $8.73 | +134% |
| 2025 | $8.73 | $4.04 | -54% |
| 2026 YTD | $4.04 | $8.29 | +105% |
TKNO has the edge over LLY on returns for 2026, with the stronger performance.